PP01.120: Global Phase 2 Randomized Trial of Pumitamig (BNT327/BMS986545; PD-L1 x VEGF-A bsAb) + Chemotherapy for 1L ES-SCLC: Dose Optimization Analysis

Journal of Thoracic Oncology 2026

View at publisher
Authors: J. Heymach, B.C. Cho, A. Sezer, C. Karacin, Y. Lee, T. Çil, O. Ozyilkan, C. Arslan, G.-W. Lee, B. Basak Oven, N. Pavlakis, İ. Hacıbekiroğlu
+17 more O. Yazıcı, K.N. Franks, A. Greystoke, M. Moore, J.T. D’Olimpio, S. Koride, S. Koseoglu, C. Delle Fratte, C. Pütter, E. Engmann, U.C. Dimkpa, S. Vlassak, C.-N. Gann, I. Celik, И. Дай, Ö. Türeci, U. Sahin
DOI: 10.1016/j.jtho.2026.103854
Cited by: 1

Fields of Study & Subjects

Lung Cancer Research Studies PARP inhibition in cancer therapy Prostate Cancer Treatment and Research

Publication details

Journal / source
Journal of Thoracic Oncology
Publisher
Elsevier BV
Volume
21
Issue
5
Pages
103854–103854
Publication date
1 May 2026
Language
EN